시장보고서

상품코드

1761169

세계의 체외 폐 모델 시장 : 시장 규모, 예측, 점유율, 동향, 성장기회 분석 보고서 - 유형별, 용도별, 최종 사용자별, 지역별(2021-2031년)

In Vitro Lung Models Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, End User, and Geography

발행일: 2025년 06월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 231 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

체외 폐 모델 시장 규모는 2024년 4억 4,635만 달러로 평가되었고, 2031년에는 15억 3,011만 달러에 이를 것으로 예측됩니다. 이 시장은 2025-2031년 CAGR 19.4%로 성장할 것으로 추정됩니다. 시장 성장을 촉진하는 주요 요인으로는 호흡기 질환 급증, 동물 실험을 대체할 체외 폐 모델의 채택 증가 등을 들 수 있습니다. 게다가 종양학에서의 3D 배양 및 AI 응용은 예측 기간 동안 시장을 끌어올릴 가능성이 높습니다. 그러나 숙련된 전문가의 부족은 시장의 억제 요인 중 하나입니다.

Global Initiative on Chronic Obstructive Lung Disease(만성 폐색성 폐질환에 관한 세계 이니셔티브)가 발표한 보고서에 따르면, 폐색성 폐질환(COPD)을 앓고 있는 사람은 6,500만 명에 이르며, 매년 300만 명 가까이 이 질환으로 사망하고 있어 세계 제4위의 사망 원인이 되고 있습니다. 2023년 미국폐협회 데이터에 따르면, 약 3,400만 명의 미국인이 천식이나 COPD 등 만성 폐질환을 앓고 있습니다. 2022년에는 미국 인구의 4.6%인 1,170만 명의 성인이 COPD 진단을 받았습니다. 2020년에 European Respiratory Journal에 게재된 논문에 의하면, 3,658만 명의 유럽인이 COPD에 이환했다고 보고되었으며, 2050년에는 4,945만 명에 달할 것으로 예측되고 있어 상대적으로 35.2% 증가하게 됩니다. 개발도상국에서의 흡연 보급과 고소득 국가에서의 고령화에 따라 COPD 유병률은 향후 40년간 상승할 것으로 예측되고 있습니다. 세계보건기구(WHO)의 추계에 따르면 COPD는 2030년까지 세계의 주요 사인 중 하나가 될 전망이며, 2060년까지 COPD 및 관련 질환에 의한 사망자는 연간 540만 명을 넘는 것으로 추정되고 있습니다.

따라서 호흡기 질환은 질병의 메커니즘을 이해하고 효과적인 치료법을 개발하기 위한 고급 연구 모델 수요에 박차를 가하고 있습니다.

정밀 절단 폐 슬라이스(PCLS)와 같은 시험관 내 폐 모델은 기도 수축과 염증 연구를 가능하게 하고 천식 및 기타 호흡기 질환에 대한 새로운 치료 표적의 평가를 용이하게 합니다. 렁 온 칩은 인간 폐의 생리적 상태를 재현하기 위해 개발되었습니다. 미시간 대학의 'lung-on-a-chip' 디바이스는 미세한 유로를 갖는 플라스틱 칩 상에서 배양한 인간 폐 조직 세포를 이용해 폐 속의 상태를 시뮬레이션하고 질환에 대한 새로운 지견을 제공하는 것입니다. 이처럼 효과적인 치료와 연구모델에 대한 수요의 증대가 시험관 내 폐모델 시장의 성장을 뒷받침하고 있습니다.

게다가, 2차원(2D) 세포 배양과 단층 배양은 비용 효율적이고, 처리량이 높고, 복제가 용이하며, 결과의 해석이 용이하기 때문에 세포 생물학에서 질환의 연구나 약제 스크리닝에 널리 이용되고 있습니다. 그렇지만, 살아있는 환자 종양의 3차원 종양 미소 환경(TME)에 존재하는 동적 상호작용의 복잡한 네트워크를 재현하기에는 불충분합니다. 이 측면은 암의 거동이나 약물 반응을 모델링하거나 환자의 생검에서 암세포주를 분리해 2차원 배양으로 유지하는 능력을 제한하고 있습니다. 기존의 2차원 세포 배양은 기초적인 것이기는 하지만 in vivo에서의 폐암을 특징짓는 복잡한 TME와 세포 상호작용을 재현하기에는 불충분합니다. 암 연구가 진보함에 따라 동물 모델 작성에 이용되는 동물의 수도 증가하고 있습니다. 이 동물들에는 마우스, 레트, 기타 유사종이 포함됩니다. 그렇지만, 동물 모델은 전임상 시험에서 얻은 지견을 효과적인 임상 치료에 연결시키는 성공률이 낮습니다. 이러한 한계에 대처하기 위해 연구는 보다 생리학적으로 적절한 인간 체외 모델(3D 세포 배양 모델)-스페로이드, 오르가노이드, 종양세포, 마이크로 유체 시스템 등-으로 이행하고 있으며, 이들은 임상에서 관찰되는 TME, 유전자 발현, 약물 응답을 보다 잘 모방하고 있습니다. 이러한 모델은 특히 폐암 연구에서 약제의 유효성을 검증하고 전임상 시험을 개선하기 위해 필수적입니다. 약제 스크리닝에 있어서 3D 모델의 통합은 2D 배양으로부터 얻은 지견을 검증하고 항암제의 효과를 평가하기 위해서 불가결합니다. 이러한 접근법은 암 치료제의 스크리닝에 유익하다는 것이 증명되고 있으며, 폐암 연구와 치료 개발의 미래를 형성하는 매우 중요한 도구로 대두되고 있습니다. 폐암 약리학 연구에서 3D 세포 배양 모델의 사용은 폐질환의 이해와 치료에 대한 접근 방식의 패러다임 변화를 의미합니다.

경쟁업체별 분석에서는 제품 포트폴리오(제품 만족도, 제품 특징, 이용가능성), 최근 시장 동향(합병 및 인수, 신제품 출시 및 강화, 투자 및 자금 조달, 수상, 합의, 제휴 및 협력, 인지, 확대), 경쟁 구도의 보다 좋은 의사결정과 이해를 돕는 지리적 존재감에 근거해 시험관내 폐모델 시장을 평가 및 분류하고 있습니다. 본 보고서에서는, 세계의 시험관내 폐모델 시장에 있어서의 주요 벤더의 최근의 중요한 동향과 혁신에 대해 깊이 조사하고 있습니다. 주요 시장 기업으로는 MatTek Corp, Lonza Group AG, Emulate, Inc, CN Bio Innovations Ltd, PromoCell GmbH, Charles River Laboratories International Inc, MIMETAS BV, InSphero AG, Organovo Holdings Inc, Draper, Inc, Epithelix, AlveoliX AG, American Type Culture Collection(ATCC)입니다.

유형에 따라 시장은 3D 모델과 2D 모델로 나뉩니다. 3D 모델은 2024년 체외 폐 모델 시장에서 가장 큰 점유율을 차지했으며, 2024-2031년에 가장 높은 CAGR을 나타낼 것으로 예측됩니다.

3D 폐 모델은 인간 폐 조직의 복잡한 구조와 세포 상호작용을 정확하게 재현하고 있습니다. 생리학적 연관성이 강화되고 있기 때문에 창약, 독성 시험, 질환 모델링에 매우 유용합니다. 3D 폐 모델의 주요 종류로는 스페로이드, 오르가노이드, 정밀 절단 폐 슬라이스(PCLS) 등이 있습니다. 3D 모델에서 세포는 3차원 구조 내에서 배양되기 때문에 기존 2D 모델에는 없는 장점이 있습니다. 이러한 모델은 폐의 구조나 미소 환경을 충실히 재현하고 있어 생리학적 조건의 정확한 시뮬레이션이 가능합니다. 그 결과 3D 모델을 이용한 약물 및 치료 연구는 2D 모델이나 동물 모델에서 얻은 결과보다 더 정확하고 신뢰성 있는 결과를 가져오는 경향이 있습니다.

체외 폐 모델 시장은 용도별로, 창약 및 독성 연구, 생리학적 연구, 재생 의료, 기타로 구분됩니다. 2024년의 체외 폐 모델 시장에서는 창약 및 독성 연구 분야가 최대의 점유율을 차지했습니다.

최종 사용자별로 체외 폐 모델 시장은 제약 및 바이오테크놀러지 기업, 학술기관 및 연구기관, 기타로 구분됩니다. 2024년 체외 폐 모델 시장에서는 제약 및 바이오 기업 부문이 최대 점유율을 차지했습니다.

체외 폐 모델 시장에서 사업을 전개하는 기업은 다양한 유기적 및 무기적 전략을 채용하고 있습니다. 유기적 전략에는 주로 제품 출시 및 제품 승인이 포함됩니다. 시장에서 볼 수 있는 무기적인 성장 전략은 인수, 제휴, 파트너십입니다. 이러한 성장 전략에 의해, 시장 참가 기업은 사업을 확대해, 지리적 존재감을 높이는 것과 동시에, 시장 전체의 성장에 공헌할 수 있습니다. 게다가 인수나 제휴 등의 전략은 고객 기반을 강화하고 제품 포트폴리오를 확대하는 데 도움이 되고 있습니다. 시험관 내 폐모델 시장의 주요 기업에 의한 중요한 발전의 일부를 이하에 제시합니다.

2024년 9월, 시험관내 인간 조직의 개발을 전문으로 하는 바이오테크놀러지 기업인 MatTek Life Sciences사는 중국을 거점으로 하는 생명과학 연구소인 CellEx사에 동사의 기관형 인간 조직을 라이선싱하는 것을 발표했습니다. 이 전략적 제휴는 연구 개발, 의약품 개발, 안전성 평가 용도에 있어서 인간 조직의 진보 및 이용에 획기적인 사건입니다.

2023년 6월 차세대 체외 모델 제공업체인 에뮬레이트사는 조기 액세스 프로그램을 통해 Emulate Chip-A1 Accessible Chip의 발매를 발표했습니다. 이 새로운 Organ-Chip의 디자인은 스트레치나 플로우라고 하는 생체역학적 힘을 이용해 조직과 혈관의 인터페이스를 모델화한 오리지널의 Chip-S1을 확장한 것으로, 유저는 상피 배양 챔버내에서 보다 두꺼운 조직을 제작해, 국소 투여나 에어로졸화 등의 약물 치료의 옵션을 추가할 수가 있습니다.

체외 폐 모델 시장-주요 시장 역학
시장 성장 촉진요인
- 호흡기 질환의 급증
- 동물실험의 대안으로서 체외 모델 채용 증가
시장 성장 억제요인
- 숙련 전문가의 부족
시장 기회
- 체외 모델에 대한 자금 조달 및 투자 급증
향후 동향
- 종양학에서의 3D 배양 및 AI의 응용
성장 촉진요인 및 억제요인의 영향

제6장 세계의 체외 폐 모델 시장 : 시장 분석

체외 폐 모델 시장 수익(2021-2031년)
체외 폐 모델 시장 예측 분석

제7장 체외 폐 모델 시장 분석 : 유형별

3D 모델
2D 모델

제8장 체외 폐 모델 시장 분석 : 용도별

창약 및 독성 연구
생리학 연구
재생 의료
기타

9장 체외 폐 모델 시장 분석 : 최종 사용자별

제약 및 바이오테크놀러지 기업
학술기관 및 연구기관
기타

제10장 체외 폐 모델 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 아시아태평양의 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 업계 정세

신제품 개발
합병 및 인수
파트너십 및 제휴
기타 사업 전략

제12장 경쟁 구도

세계의 기업 점유율 분석(2024년)

제13장 기업 프로파일

MatTek Corp
Lonza Group AG
Emulate, Inc.
CN Bio Innovations Ltd
Merck KGaA
PromoCell GmbH
Charles River Laboratories International Inc
MIMETAS BV
InSphero AG
Organovo Holdings Inc
Draper, Inc.
TissUse GmbH
Epithelix
AlveoliX AG
American Type Culture Collection(ATCC)

제14장 부록

AJY 25.07.10

The In Vitro lung models market size is projected to reach US$ 1,530.11 million by 2031 from US$ 446.35 million in 2024. The market is estimated to register a CAGR of 19.4% during 2025-2031. Major factors driving the market growth include a surging prevalence of respiratory diseases and the rising adoption of in vitro models as an alternative to animal testing. Further, Applications of 3D cultures and AI in oncology is likely to boost the market during the forecast period. However, lack of skilled professionals are among the market deterrents.

According to a report published by the Global Initiative on Chronic Obstructive Lung Disease, ~65 million people suffer from obstructive pulmonary disease (COPD), and nearly 3 million people die from the disease each year, making it the fourth leading cause of mortality worldwide. According to the 2023 American Lung Association data, ~34 million Americans were affected by chronic lung diseases such as asthma and COPD. In 2022, ~11.7 million adults, or 4.6% of the population in the US, were diagnosed with COPD. As per an article published in the European Respiratory Journal in 2020, 36.58 million Europeans were reported to have COPD, which is projected to reach 49.45 million by 2050, representing a 35.2% relative increase. With the growing prevalence of smoking in developing countries and the aging population in high-income countries, the COPD prevalence is projected to rise over the next forty years. As per the World Health Organization (WHO) estimates, COPD will become one of the leading causes of death worldwide by 2030, and it is estimated that by 2060, there will be more than 5.4 million deaths yearly due to COPD and related conditions.

Therefore, respiratory diseases is spurring the demand for advanced research models to understand disease mechanisms and develop effective treatments.

In vitro lung models, such as precision-cut lung slices (PCLS), allow the study of airway constriction and inflammation, facilitating the evaluation of novel therapeutic targets for asthma and other respiratory conditions. Lung-on-a-chip devices have been developed to replicate the physiological conditions of the human lung. The University of Michigan's "lung-on-a-chip" device uses human lung-tissue cells cultured on a plastic chip with microscopic channels to simulate the conditions inside the lungs, providing new insights into diseases. Thus, the increasing demand for effective treatments and research models fuels the growth of the in vitro lung model market.

Moreover, two-dimensional (2D) cell cultures, or monolayers, are widely used in cellular biology to study diseases and for drug screening due to their cost-effectiveness, high throughput, easy replication, and results interpretation. However, they fall short in replicating the complex network of dynamic interactions present in the three-dimensional tumor microenvironment (TME) of living patient tumors. This aspect limits their ability to model cancer behavior and drug responses, as well as to isolate and maintain cancer cell lines from patient biopsies in 2D cultures. Traditional 2D cell cultures, while foundational, fall short in replicating the intricate TME and cellular interactions that characterize lung cancers in vivo. As cancer research advances, an increasing number of animals are being utilized in the creation of animal models. These animals include mice, rats, and other similar species. However, animal models exhibit low success rates in translating preclinical findings into effective clinical treatments; this has raised concerns about their reliability as predictors of human responses. To address these limitations, research is shifting toward more physiologically relevant human in vitro models (3D cell culture models)-such as spheroids, organoids, tumoroids, and microfluidic systems-that better mimic the TME, gene expression, and drug responses observed clinically. These models are critical for validating drug efficacy and improving preclinical testing, especially in lung cancer research. Integrating 3D models in drug screening is essential to validate findings from 2D cultures and assess the effects of anticancer drugs. Such approaches have proven to be fruitful for cancer drug screening and are emerging as a pivotal tool in shaping the future of lung cancer research and therapeutic development. The use of 3D cell culture models in lung cancer pharmacology research represents a paradigm shift in the approach toward understanding and treating lung diseases.

The comparative company analysis evaluates and categorizes the in vitro lung models market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global in vitro lung models market. The key market players are MatTek Corp, Lonza Group AG, Emulate, Inc, CN Bio Innovations Ltd, PromoCell GmbH, Charles River Laboratories International Inc, MIMETAS BV, InSphero AG, Organovo Holdings Inc, Draper, Inc, Epithelix, AlveoliX AG, and American Type Culture Collection (ATCC).

Based on type, the market is divided into 3D Models and 2D Models. The 3D Models segment held the largest In Vitro Lung Model Market share in 2024, and it is expected to register the highest CAGR during 2024-2031.

3D lung models replicate the complex architecture and cellular interactions of human lung tissue accurately. The enhanced physiological relevance makes them invaluable for drug discovery, toxicity testing, and disease modeling. The primary types of 3D lung models include spheroids, organoids, and precision-cut lung slices (PCLS). In 3D models, cells are cultured within a three-dimensional structure, offering advantages over traditional 2D models. These models closely replicate the architecture and microenvironment of the lung, enabling accurate simulation of physiological conditions. As a result, drug and therapeutic studies using 3D models tend to yield more accurate and reliable results than those derived from 2D models or animal models.

By application, In Vitro Lung Model market is segmented into drug discovery and toxicology studies, physiological research, regenerative medicine, and others. The drug discovery and toxicology studies segment held the largest share of the in vitro lung model market in 2024.

Per end user, In Vitro Lung Model market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others. The pharmaceutical and biotechnology companies segment held the largest share of the In Vitro lung model market in 2024.

Various organic and inorganic strategies are adopted by companies operating in the in vitro lung models market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the in vitro lung models market are listed below.

In September 2024, MatTek Life Sciences, a biotech company specializing in the development of in vitro human tissues, announced the licensing of its organotypic human tissues to CellEx, a life science laboratory based in China. This strategic collaboration marks a milestone in the advancement and utilization of human tissues for research, pharmaceutical development, and safety assessment applications.

In June 2023, Emulate, Inc., a provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1 Accessible Chip through an early access program. This new Organ-Chip design expands on the original Chip-S1-which models tissue-vascular interfaces with relevant biomechanical forces such as stretch and flow-by allowing users to create thicker tissues within the epithelial culture chamber and apply additional drug treatment options, including topical or aerosolized applications.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. In-Vitro Lung Model Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Regulatory Scenario

5. In-Vitro Lung Model Market - Key Market Dynamics

5.1 In-Vitro Lung Model Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Surging Prevalence of Respiratory Diseases
- 5.2.2 Rising Adoption of In Vitro Models as an Alternative to Animal Testing
5.3 Market Restraints
- 5.3.1 Lack of Skilled Professionals
5.4 Market Opportunities
- 5.4.1 Surging Funding and Investments for In Vitro Models
5.5 Future Trends
- 5.5.1 Application of 3D Cultures and AI in Oncology
5.6 Impact of Drivers and Restraints:

6. In-Vitro Lung Model Market - Global Market Analysis

6.1 In-Vitro Lung Model Market Revenue (US$ Million), 2021-2031
6.2 In-Vitro Lung Model Market Forecast Analysis

7. In-Vitro Lung Model Market Analysis - by Type

7.1 3D Model
- 7.1.1 Overview
- 7.1.2 3D Model: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
7.2 2D Model
- 7.2.1 Overview
- 7.2.2 2D Model: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)

8. In-Vitro Lung Model Market Analysis - by Application

8.1 Drug Discovery and Toxicology Studies
- 8.1.1 Overview
- 8.1.2 Drug Discovery and Toxicology Studies: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Physiological Research
- 8.2.1 Overview
- 8.2.2 Physiological Research: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Regenerative Medicine
- 8.3.1 Overview
- 8.3.2 Regenerative Medicine: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)

9. In-Vitro Lung Model Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Academic and Research Institutes
- 9.2.1 Overview
- 9.2.2 Academic and Research Institutes: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)

10. In-Vitro Lung Model Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America In-Vitro Lung Model Market Overview
- 10.2.2 North America: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
- 10.2.3 North America: In-Vitro Lung Model Market Breakdown, by Type
  - 10.2.3.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
- 10.2.4 North America: In-Vitro Lung Model Market Breakdown, by Application
  - 10.2.4.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
- 10.2.5 North America: In-Vitro Lung Model Market Breakdown, by End User
  - 10.2.5.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
- 10.2.6 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.2.1 United States: In-Vitro Lung Model Market Breakdown, by Type
    - 10.2.6.2.2 United States: In-Vitro Lung Model Market Breakdown, by Application
    - 10.2.6.2.3 United States: In-Vitro Lung Model Market Breakdown, by End User
  - 10.2.6.3 Canada: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.3.1 Canada: In-Vitro Lung Model Market Breakdown, by Type
    - 10.2.6.3.2 Canada: In-Vitro Lung Model Market Breakdown, by Application
  - 10.2.6.4 Mexico: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.4.1 Mexico: In-Vitro Lung Model Market Breakdown, by Type
    - 10.2.6.4.2 Mexico: In-Vitro Lung Model Market Breakdown, by Application
    - 10.2.6.4.3 Mexico: In-Vitro Lung Model Market Breakdown, by End User
10.3 Europe
- 10.3.1 Europe In-Vitro Lung Model Market Overview
- 10.3.2 Europe: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
- 10.3.3 Europe: In-Vitro Lung Model Market Breakdown, by Type
  - 10.3.3.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
- 10.3.4 Europe: In-Vitro Lung Model Market Breakdown, by Application
  - 10.3.4.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
- 10.3.5 Europe: In-Vitro Lung Model Market Breakdown, by End User
  - 10.3.5.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
- 10.3.6 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.2.1 Germany: In-Vitro Lung Model Market Breakdown, by Type
    - 10.3.6.2.2 Germany: In-Vitro Lung Model Market Breakdown, by Application
    - 10.3.6.2.3 Germany: In-Vitro Lung Model Market Breakdown, by End User
  - 10.3.6.3 France: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.3.1 France: In-Vitro Lung Model Market Breakdown, by Type
    - 10.3.6.3.2 France: In-Vitro Lung Model Market Breakdown, by Application
    - 10.3.6.3.3 France: In-Vitro Lung Model Market Breakdown, by End User
  - 10.3.6.4 United Kingdom: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.4.1 United Kingdom: In-Vitro Lung Model Market Breakdown, by Type
    - 10.3.6.4.2 United Kingdom: In-Vitro Lung Model Market Breakdown, by Application
    - 10.3.6.4.3 United Kingdom: In-Vitro Lung Model Market Breakdown, by End User
  - 10.3.6.5 Italy: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.5.1 Italy: In-Vitro Lung Model Market Breakdown, by Type
    - 10.3.6.5.2 Italy: In-Vitro Lung Model Market Breakdown, by Application
    - 10.3.6.5.3 Italy: In-Vitro Lung Model Market Breakdown, by End User
  - 10.3.6.6 Spain: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.6.1 Spain: In-Vitro Lung Model Market Breakdown, by Type
    - 10.3.6.6.2 Spain: In-Vitro Lung Model Market Breakdown, by Application
    - 10.3.6.6.3 Spain: In-Vitro Lung Model Market Breakdown, by End User
  - 10.3.6.7 Rest of Europe: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: In-Vitro Lung Model Market Breakdown, by Type
    - 10.3.6.7.2 Rest of Europe: In-Vitro Lung Model Market Breakdown, by Application
    - 10.3.6.7.3 Rest of Europe: In-Vitro Lung Model Market Breakdown, by End User
10.4 Asia Pacific
- 10.4.1 Asia Pacific In-Vitro Lung Model Market Overview
- 10.4.2 Asia Pacific: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
- 10.4.3 Asia Pacific: In-Vitro Lung Model Market Breakdown, by Type
  - 10.4.3.1 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
- 10.4.4 Asia Pacific: In-Vitro Lung Model Market Breakdown, by Application
  - 10.4.4.1 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
  - 10.4.4.2 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
- 10.4.5 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.4.5.1 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.4.5.2 China: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.5.2.1 China: In-Vitro Lung Model Market Breakdown, by Type
    - 10.4.5.2.2 China: In-Vitro Lung Model Market Breakdown, by Application
    - 10.4.5.2.3 China: In-Vitro Lung Model Market Breakdown, by End User
  - 10.4.5.3 Japan: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.5.3.1 Japan: In-Vitro Lung Model Market Breakdown, by Type
    - 10.4.5.3.2 Japan: In-Vitro Lung Model Market Breakdown, by Application
    - 10.4.5.3.3 Japan: In-Vitro Lung Model Market Breakdown, by End User
  - 10.4.5.4 India: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.5.4.1 India: In-Vitro Lung Model Market Breakdown, by Type
    - 10.4.5.4.2 India: In-Vitro Lung Model Market Breakdown, by Application
    - 10.4.5.4.3 India: In-Vitro Lung Model Market Breakdown, by End User
  - 10.4.5.5 South Korea: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.5.5.1 South Korea: In-Vitro Lung Model Market Breakdown, by Type
    - 10.4.5.5.2 South Korea: In-Vitro Lung Model Market Breakdown, by Application
    - 10.4.5.5.3 South Korea: In-Vitro Lung Model Market Breakdown, by End User
  - 10.4.5.6 Australia: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.5.6.1 Australia: In-Vitro Lung Model Market Breakdown, by Type
    - 10.4.5.6.2 Australia: In-Vitro Lung Model Market Breakdown, by Application
    - 10.4.5.6.3 Australia: In-Vitro Lung Model Market Breakdown, by End User
  - 10.4.5.7 Rest of APAC: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.5.7.1 Rest of APAC: In-Vitro Lung Model Market Breakdown, by Type
    - 10.4.5.7.2 Rest of APAC: In-Vitro Lung Model Market Breakdown, by Application
    - 10.4.5.7.3 Rest of APAC: In-Vitro Lung Model Market Breakdown, by End User
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa In-Vitro Lung Model Market Overview
- 10.5.2 Middle East and Africa: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
- 10.5.3 Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Type
  - 10.5.3.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
- 10.5.4 Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Application
  - 10.5.4.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
- 10.5.5 Middle East and Africa: In-Vitro Lung Model Market Breakdown, by End User
  - 10.5.5.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
- 10.5.6 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: In-Vitro Lung Model Market Breakdown, by Type
    - 10.5.6.2.2 Saudi Arabia: In-Vitro Lung Model Market Breakdown, by Application
    - 10.5.6.2.3 Saudi Arabia: In-Vitro Lung Model Market Breakdown, by End User
  - 10.5.6.3 South Africa: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.3.1 South Africa: In-Vitro Lung Model Market Breakdown, by Type
    - 10.5.6.3.2 South Africa: In-Vitro Lung Model Market Breakdown, by Application
    - 10.5.6.3.3 South Africa: In-Vitro Lung Model Market Breakdown, by End User
  - 10.5.6.4 United Arab Emirates: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: In-Vitro Lung Model Market Breakdown, by Type
    - 10.5.6.4.2 United Arab Emirates: In-Vitro Lung Model Market Breakdown, by Application
    - 10.5.6.4.3 United Arab Emirates: In-Vitro Lung Model Market Breakdown, by End User
  - 10.5.6.5 Rest of Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Type
    - 10.5.6.5.2 Rest of Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Application
    - 10.5.6.5.3 Rest of Middle East and Africa: In-Vitro Lung Model Market Breakdown, by End User
10.6 South and Central America
- 10.6.1 South and Central America In-Vitro Lung Model Market Overview
- 10.6.2 South and Central America: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
- 10.6.3 South and Central America: In-Vitro Lung Model Market Breakdown, by Type
  - 10.6.3.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
- 10.6.4 South and Central America: In-Vitro Lung Model Market Breakdown, by Application
  - 10.6.4.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
- 10.6.5 South and Central America: In-Vitro Lung Model Market Breakdown, by End User
  - 10.6.5.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
- 10.6.6 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.2.1 Brazil: In-Vitro Lung Model Market Breakdown, by Type
    - 10.6.6.2.2 Brazil: In-Vitro Lung Model Market Breakdown, by Application
    - 10.6.6.2.3 Brazil: In-Vitro Lung Model Market Breakdown, by End User
  - 10.6.6.3 Argentina: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.3.1 Argentina: In-Vitro Lung Model Market Breakdown, by Type
    - 10.6.6.3.2 Argentina: In-Vitro Lung Model Market Breakdown, by Application
    - 10.6.6.3.3 Argentina: In-Vitro Lung Model Market Breakdown, by End User
  - 10.6.6.4 Rest of South and Central America: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: In-Vitro Lung Model Market Breakdown, by Type
    - 10.6.6.4.2 Rest of South and Central America: In-Vitro Lung Model Market Breakdown, by Application
    - 10.6.6.4.3 Rest of South and Central America: In-Vitro Lung Model Market Breakdown, by End User

11. Industry Landscape

11.1 Overview
11.2 New Product Development
11.3 Merger and Acquisition
11.4 Partnerships and Collaborations
11.5 Other Business Strategies

12. Competitive Landscape

12.1 Global Company Market Share Analysis, 2024

13. Company Profiles

13.1 MatTek Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Lonza Group AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Emulate, Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 CN Bio Innovations Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck KGaA
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 PromoCell GmbH
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
13.7 Charles River Laboratories International Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 MIMETAS BV
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 InSphero AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Organovo Holdings Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Draper, Inc.
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 TissUse GmbH
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
13.13 Epithelix
- 13.13.1 Key Facts
- 13.13.2 Business Description
- 13.13.3 Financial Overview
- 13.13.4 SWOT Analysis
- 13.13.5 Key Developments
13.14 AlveoliX AG
- 13.14.1 Key Facts
- 13.14.2 Business Description
- 13.14.3 Products and Services
- 13.14.4 Financial Overview
- 13.14.5 SWOT Analysis
- 13.14.6 Key Developments
13.15 American Type Culture Collection (ATCC)
- 13.15.1 Key Facts
- 13.15.2 Business Description
- 13.15.3 Products and Services
- 13.15.4 Financial Overview
- 13.15.5 SWOT Analysis

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms